Literature DB >> 22885065

Loss of Rb cooperates with Ras to drive oncogenic growth in mammalian cells.

Melissa J Collins1, Ilaria Napoli, Sara Ribeiro, Sinead Roberts, Alison C Lloyd.   

Abstract

BACKGROUND: The p53, Rb, and Ras/PI3K pathways are implicated in the development of the majority of human cancers. A number of studies have established that these pathways cooperate at the level of the cell cycle leading to loss of normal proliferative controls. Here we have investigated how these signals influence a second critical component of tumor formation-cell growth.
RESULTS: We find that oncogenic Ras is sufficient to drive growth via the canonical growth pathway, PI3K-AKT-TOR; however, it does so relatively weakly and p53 loss does not drive cell growth at all. Importantly, we identify a novel role for the Rb family of tumor suppressors in directing cell growth via a signaling pathway distinct from PI3K-AKT-TOR and via an E2F-independent mechanism. However, we find that strong, sustained growth requires Rb loss together with Ras signaling, identifying an additional mechanism by which these oncogenic pathways cooperate and a critical role for Ras in preserving the uptake of extracellular nutrients required for biogenesis.
CONCLUSIONS: We have identified a new role for the Rb family in cell biogenesis and show that, as for other processes associated with tumor development, oncogenic cell growth is dependent on cooperating oncogenes.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22885065     DOI: 10.1016/j.cub.2012.07.040

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  1 in total

1.  Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.

Authors:  Michael S Lee; Timothy L Helms; Ningping Feng; Jason Gay; Qing Edward Chang; Feng Tian; Ji Y Wu; Carlo Toniatti; Timothy P Heffernan; Garth Powis; Lawrence N Kwong; Scott Kopetz
Journal:  Oncotarget       Date:  2016-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.